- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07940348
Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery (SPAR-Breast)
Dosimetric Comparison of Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery: A Prospective Paired Study
This study aims to compare two positions used for whole-breast radiation therapy in Thai women who have undergone breast-conserving surgery: lying on the back (supine) and lying face down (prone).
Radiation therapy after breast-conserving surgery helps reduce the risk of breast cancer returning. However, some radiation may reach nearby organs, particularly the heart and lungs. The position used during treatment may affect how much radiation these organs receive.
In this study, 24 women will undergo radiation treatment planning CT scans in both the supine and prone positions. Researchers will create a radiation treatment plan for each position and compare how well the plans cover the breast while minimizing radiation exposure to the heart and lungs. Each participant will receive actual radiation treatment in only one of the two positions, selected based on treatment planning results and clinical suitability.
The study will also assess patient comfort, positioning accuracy, treatment setup time, and treatment-related side effects.
The findings may help identify which patients are more likely to benefit from prone positioning and support individualized breast radiation treatment planning in Thai women.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a prospective paired within-patient dosimetric study comparing supine and prone whole-breast radiotherapy in Thai women after breast-conserving surgery.
Each participant will undergo CT simulation in both the supine and prone positions. A three-dimensional conformal radiotherapy plan will be generated for each position using the same planning approach. The two plans will first be evaluated for acceptable target coverage. They will then be compared according to radiation exposure to organs at risk, with primary consideration given to the heart and ipsilateral lung and secondary consideration given to the contralateral lung and contralateral breast.
The treatment position used for actual radiotherapy will be selected using a predefined plan-comparison algorithm based on target coverage and organ-at-risk dose criteria. If both plans are otherwise comparable, patient preference may be used as a final decision factor. The participant will receive treatment in only one selected position.
The study will also explore whether anatomical characteristics, including chest wall and breast-related measurements, are associated with greater dosimetric benefit from prone positioning. Additional assessments include treatment setup time, positioning accuracy, patient comfort and preference, and treatment-related toxicity.
The study is intended to provide institution-specific data on individualized selection of breast radiotherapy position in Thai women rather than assuming that either supine or prone positioning is preferable for all patients.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tanun Jitwatcharakomol, MD
- Numéro de téléphone: +66 90 962 3000
- E-mail: tanun.jit@mahidol.ac.th
Sauvegarde des contacts de l'étude
- Nom: Natawat Sukumtanakul, MD
- Numéro de téléphone: +66 90 985 6598
- E-mail: d.natawats@gmail.com
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologically confirmed breast carcinoma or ductal carcinoma in situ (DCIS)
- Status post breast-conserving surgery
- Planned adjuvant breast-only radiotherapy
- No indication for regional nodal irradiation
- Preoperative breast size corresponding to bra cup A-B, defined by the patient's preoperative bra size or a bust-minus-underbust circumference difference of <14 cm
- Age ≥18 years
Exclusion Criteria:
- Planned treatment using Deep Inspiration Breath Hold (DIBH)
- Bilateral breast cancer
- Previous radiotherapy to the ipsilateral breast
- Unable to tolerate either the prone or supine position
- Breast volume >750 cm³
- Pre-existing heart disease or lung disease
- Active connective tissue disease
- Pregnant or found to be pregnant
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Supine and Prone Whole-Breast Radiotherapy Planning
All participants will undergo CT simulation and treatment planning in both the supine and prone positions. The two plans will be compared for target coverage and radiation dose to organs at risk, including the heart and ipsilateral lung. Actual whole-breast radiotherapy will be delivered in only one selected position based on predefined plan-selection criteria and clinical suitability. |
Participants will undergo CT simulation in both supine and prone positions after breast-conserving surgery. Whole-breast radiotherapy plans will be generated for both positions using 3-dimensional conformal radiotherapy (3D-CRT). Target coverage and organ-at-risk dosimetric parameters will be compared between the two plans. The treatment position will be selected according to predefined target coverage and organ-at-risk criteria. Participants will receive actual radiotherapy in the selected position only. The prescribed whole-breast dose is 40 Gy in 15 fractions, with a simultaneous integrated boost to 48 Gy in selected patients. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean Heart Dose in Supine Versus Prone Treatment Plans
Délai: within 4 weeks after both CT simulations
|
Mean radiation dose to the heart, measured in Gray (Gy), will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. The mean heart dose will be compared between the two positions while maintaining acceptable target coverage. |
within 4 weeks after both CT simulations
|
|
Mean Ipsilateral Lung Dose in Supine Versus Prone Treatment Plans
Délai: within 4 weeks after both CT simulations
|
Radiation dose to the lung on the same side as the treated breast will be assessed from the dose-volume histogram for both supine and prone treatment plans. Dosimetric parameters will include mean ipsilateral lung dose, and will be compared within the same participant while maintaining acceptable target coverage. |
within 4 weeks after both CT simulations
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PTV_Eval V95 in Supine Versus Prone Treatment Plans
Délai: within 4 weeks after both CT simulations
|
PTV_Eval V95, defined as the percentage of PTV_Eval receiving at least 95% of the prescribed dose, will be obtained from the dose-volume histogram for both the supine and prone treatment plans within the same participant. PTV_Eval V95 will be compared between the two positions. The unit of measure is percentage (%). |
within 4 weeks after both CT simulations
|
|
Treatment time from initial setup to treatment completion
Délai: within 4 weeks after treatment completion
|
Time required for patient positioning and setup until treatment is completed will be recorded and compared between the supine and prone positions. Time will be reported in minutes. |
within 4 weeks after treatment completion
|
|
translational X Positioning Accuracy
Délai: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational X axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
translational Y Positioning Accuracy
Délai: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Y axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
translational Z Positioning Accuracy
Délai: within 4 weeks after treatment completion
|
Positioning accuracy will be assessed using setup verification imaging. Residual setup errors in the translational Z axis will be recorded and compared between treatment positions. Positioning Accuracy will be reported in millimeters (mm). |
within 4 weeks after treatment completion
|
|
Patient Satisfaction Score
Délai: within 1 hours after both CT simulations, and within 1 hours after treatment completion
|
Patient satisfaction will be assessed using a study-specific questionnaire. Comfort and satisfaction will be rated using a 5-point Likert scale ranging from 1 to 5, with higher scores indicating greater comfort and satisfaction with the position. |
within 1 hours after both CT simulations, and within 1 hours after treatment completion
|
|
Radiation Therapist Satisfaction
Délai: within 1 hours after treatment completion
|
Radiation therapist satisfaction with patient positioning will be assessed using a study-specific 5-point Likert satisfaction scale for the supine and prone positions. Scores range from 1 to 5, with higher scores indicating greater radiation therapist satisfaction with the positioning technique. |
within 1 hours after treatment completion
|
|
Acute Skin Toxicity using CTCAE Version 5.0 graing scale
Délai: Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
|
Acute radiation-related skin toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Radiation dermatitis will be graded from Grade 0 to Grade 5, with higher grades indicating greater severity of skin toxicity. |
Weekly during radiotherapy for about 3 weeks and at 1 month after treatment completion
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Tanun Jitwatcharakomol, MD, Mahidol University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Carcinome du sein in situ
- Tumeurs par site
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Maladies de la peau
- Maladies du sein
- Carcinome
- Tumeurs canalaires, lobulaires et médullaires
- Carcinome in situ
- Comportement
- Maladies de la peau et du tissu conjonctif
- Comportement social
- Tumeurs mammaires
- Carcinome intracanalaire non infiltrant
- Tromperie
Autres numéros d'identification d'étude
- 683/2569(IRB1)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .